Instil Bio Inc (TIL) Stock Price, Quote & News - Mboum

Company Profile

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 499 3350

Website: instilbio.com

Address:

3963 Maple Avenue, Suite 350, Dallas, United States

Magic8BallResponse Nov. 14 at 2:46 PM

0 · Reply

d_risk Nov. 13 at 1:35 PM

$TIL - Instil Bio Inc. Common Stock - 10Q - Updated Risk Factors TIL’s 10-Q risk factors now spotlight urgent funding needs, heightened clinical and regulatory risks for lead candidate 2510, deep reliance on ImmuneOnco’s China trials and manufacturing, intensifying competition in bispecific antibodies, expanded IP and patent litigation threats, and sharper focus on financial and operational uncertainties. #Biotechnology #PatentLitigation #FundingChallenges #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/TIL/10-Q/2025-11-13

0 · Reply

Bigmal1 Nov. 5 at 2:18 PM

$TIL bottom yet?

0 · Reply

BillionerOfKing Oct. 30 at 12:57 PM

$TIL Current Stock Price: $17.61 No options data available.

0 · Reply

Magic8BallResponse Oct. 15 at 11:19 PM

0 · Reply

Magic8BallResponse Oct. 13 at 2:05 PM

0 · Reply

Magic8BallResponse Oct. 9 at 8:01 PM

0 · Reply

Magic8BallResponse Oct. 9 at 7:28 PM

0 · Reply

BillionerOfKing Oct. 2 at 1:30 PM

$TIL Current Stock Price: $19.15 No options data available.

0 · Reply

360nocondom Sep. 25 at 10:01 PM

$TIL Was hoping to be able to get some profit here as previous trades was excellent. Waited for the bottom after my last 5% loss here (the first loss that broke my streak 😭), but it looks like its not coming anytime soon.

0 · Reply

Latest News on TIL

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 7:00 AM EST - 1 day ago

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Sep 10, 2025, 7:00 AM EDT - 2 months ago

Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:00 AM EDT - 3 months ago

Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

Jul 31, 2025, 6:00 AM EDT - 3 months ago

ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China

$Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors$

Jul 2, 2025, 6:00 AM EDT - 4 months ago

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Jun 11, 2025, 7:00 AM EDT - 5 months ago

Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 6 months ago

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 25, 2025, 7:09 AM EDT - 6 months ago

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 23, 2025, 7:00 AM EDT - 6 months ago

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

May 22, 2025, 6:00 AM EDT - 6 months ago

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 7:00 AM EDT - 6 months ago

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 4, 2025, 7:09 AM EST - 9 months ago

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Jan 14, 2025, 7:00 AM EST - 10 months ago

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Jan 7, 2025, 2:06 PM EST - 11 months ago

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Dec 1, 2024, 5:00 AM EST - 1 year ago

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Sep 16, 2024, 12:31 PM EDT - 1 year ago

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Sep 16, 2024, 6:00 AM EDT - 1 year ago

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Sep 13, 2024, 1:22 PM EDT - 1 year ago

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 5:00 PM EDT - 1 year ago

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 7:00 AM EDT - 1 year ago

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 5:00 PM EDT - 1 year ago

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Instil Bio Announces Strategic Update

Jan 16, 2024, 8:00 AM EST - 1 year ago

Instil Bio Announces Strategic Update

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

Dec 5, 2023, 5:00 PM EST - 2 years ago

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 5:00 PM EST - 2 years ago

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Nov 6, 2023, 7:00 AM EST - 2 years ago

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

Jun 26, 2023, 4:38 PM EDT - 2 years ago

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 31, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

Jan 31, 2023, 5:00 PM EST - 3 years ago

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

7 Cheap But Risky Biotech Stocks

Jan 18, 2023, 1:58 PM EST - 3 years ago

7 Cheap But Risky Biotech Stocks

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Jan 9, 2023, 7:00 AM EST - 3 years ago

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Dec 12, 2022, 11:45 AM EST - 3 years ago

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Dec 8, 2022, 7:00 AM EST - 3 years ago

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 14, 2022, 4:07 PM EST - 3 years ago

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 8, 2022, 6:13 PM EST - 3 years ago

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 8, 2022, 7:00 AM EST - 3 years ago

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 7, 2022, 8:59 AM EST - 3 years ago

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 2, 2022, 9:39 AM EDT - 3 years ago

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Nov 1, 2022, 5:30 PM EDT - 3 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Nov 1, 2022, 1:33 PM EDT - 3 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 1, 2022, 10:50 AM EDT - 3 years ago

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Magic8BallResponse Nov. 14 at 2:46 PM

0 · Reply

d_risk Nov. 13 at 1:35 PM

$TIL - Instil Bio Inc. Common Stock - 10Q - Updated Risk Factors TIL’s 10-Q risk factors now spotlight urgent funding needs, heightened clinical and regulatory risks for lead candidate 2510, deep reliance on ImmuneOnco’s China trials and manufacturing, intensifying competition in bispecific antibodies, expanded IP and patent litigation threats, and sharper focus on financial and operational uncertainties. #Biotechnology #PatentLitigation #FundingChallenges #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/TIL/10-Q/2025-11-13

0 · Reply

Bigmal1 Nov. 5 at 2:18 PM

$TIL bottom yet?

0 · Reply

BillionerOfKing Oct. 30 at 12:57 PM

$TIL Current Stock Price: $17.61 No options data available.

0 · Reply

Magic8BallResponse Oct. 15 at 11:19 PM

0 · Reply

Magic8BallResponse Oct. 13 at 2:05 PM

0 · Reply

Magic8BallResponse Oct. 9 at 8:01 PM

0 · Reply

Magic8BallResponse Oct. 9 at 7:28 PM

0 · Reply

BillionerOfKing Oct. 2 at 1:30 PM

$TIL Current Stock Price: $19.15 No options data available.

0 · Reply

360nocondom Sep. 25 at 10:01 PM

$TIL Was hoping to be able to get some profit here as previous trades was excellent. Waited for the bottom after my last 5% loss here (the first loss that broke my streak 😭), but it looks like its not coming anytime soon.

0 · Reply

Magic8BallResponse Sep. 24 at 2:42 PM

$SMMT $TIL ..... Reversal

0 · Reply

Bigmal1 Sep. 24 at 4:31 AM

$DRCT $CHSN $AEHL $TIL Which one to average down in?

1 · Reply

Magic8BallResponse Sep. 23 at 7:42 PM

$TIL Volume....

0 · Reply

Magic8BallResponse Sep. 23 at 1:16 PM

$TIL Back into $ATXS....

0 · Reply

Magic8BallResponse Sep. 19 at 6:56 PM

$TIL ADDED

0 · Reply

Magic8BallResponse Sep. 19 at 2:28 PM

$TIL No insider buys... directors.... nada....

0 · Reply

Magic8BallResponse Sep. 19 at 1:32 PM

$TIL Where are the insider buys?

0 · Reply

Magic8BallResponse Sep. 18 at 2:21 PM

$TIL Where are the insider buys?

0 · Reply

Magic8BallResponse Sep. 18 at 2:12 PM

$TIL No news is no news....

0 · Reply

Magic8BallResponse Sep. 17 at 5:20 PM

$TIL nice bounce off support level.... confirmation at close

0 · Reply

BillionerOfKing Sep. 17 at 4:28 PM

$TIL trade update.

0 · Reply

Magic8BallResponse Sep. 17 at 3:23 PM

$TIL Testing support. Could reverse on news. $ATXS to the moon

0 · Reply